X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AVB-S6-500 (batiraxcept), is an ultra-high affinity decoy protein that binds to GAS6, the ligand that activates AXL, hence inhibits the metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. It is being investigated for platinum-resistant ovarian cancer.
Lead Product(s): Batiraxcept,Paclitaxel
Therapeutic Area: Oncology Product Name: AVB-500
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2023
Details:
AVB-S6-500 (batiraxcept), is an ultra-high affinity decoy protein that binds to GAS6, the ligand that activates AXL, hence inhibits the metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. It is being investigated for clear cell renal cell carcinoma.
Lead Product(s): Batiraxcept,Cabozantinib,Nivolumab
Therapeutic Area: Oncology Product Name: AVB-S6-500
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Details:
AVB-500 (batiraxcept) is an ultra-high affinity decoy protein that captures GAS6, thereby potentially stopping the migration and invasion of tumor cells into healthy tissue.
Lead Product(s): Batiraxcept,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: AVB-500
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2023
Details:
AVB-500 (batiraxcept), is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents.
Lead Product(s): Batiraxcept,Cabozantinib,Nivolumab
Therapeutic Area: Oncology Product Name: AVB-S6-500
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
AVB-500 (Batiraxcept) is an ultra-high affinity decoy protein that captures GAS6, thereby potentially stopping the migration and invasion of tumor cells into healthy tissue.
Lead Product(s): Batiraxcept,Paclitaxel
Therapeutic Area: Oncology Product Name: AVB-500
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023
Details:
AVB-S6-500 (batiraxcept), for treatment of patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have progressed after 1 or 2 prior lines of systemic therapy that include both immuno-oncology (IO)-based and VEGF-TKI-based therapies.
Lead Product(s): Batiraxcept,Cabozantinib,Nivolumab
Therapeutic Area: Oncology Product Name: AVB-S6-500
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2022
Details:
Funding will be used to provide the topline readout of Phase 3 trial in PROC batiraxcept (formerly AVB-500), incremental data read outs from the Phase 1b/2 trial in clear cell renal cell cancer and expanded Phase 1b pancreatic adenocarcinoma studies anticipated in 2023.
Lead Product(s): Batiraxcept,Paclitaxel
Therapeutic Area: Oncology Product Name: AVB-500
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BVF Partners
Deal Size: $41.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 25, 2022
Details:
batiraxcept (formerly AVB-500), is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, inhibiting metastasis, tumor growth, and restoring sensitivity to anti-cancer agents.
Lead Product(s): Batiraxcept,Paclitaxel
Therapeutic Area: Oncology Product Name: AVB-S6-500
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: 3D Medicines
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
Details:
AVB-S6-500 (Batiraxcept) 15 mg/kg in combination with cabozantinib 60 mg has a manageable safety profile in previously treated ccRCC; no dose-limiting toxicities have been observed; a similar safety profile was observed across the 15 mg/kg and 20 mg/kg dose cohorts.
Lead Product(s): Batiraxcept,Cabozantinib,Nivolumab
Therapeutic Area: Oncology Product Name: AVB-S6-500
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
Batiraxcept (formerly AVB-500), is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents.
Lead Product(s): Batiraxcept,Cabozantinib,Nivolumab
Therapeutic Area: Oncology Product Name: AVB-S6-500
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
